S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
WP-1066, a Next-Generation Member of JAK-Stat Inhibitors, Induces Cell Cycle Arrest, Abrogates Proliferation, and Induces Apoptosis of Acute Myeloid Leukemia (AML) Cells.
Alessandra Ferrajoli,Stefan Faderl,Quin Van,David Harris,Waldemar Priebe,Hagop M. Kantarjian,Moshe Talpaz,Zeev Estrov +7 more
TL;DR: The data showing that WP-1066 inhibits the JAK-Stat pathway, suppresses proliferation, induces cell cycle arrest and apoptosis of AML cells, suggest that the activity of this compound warrants further exploitation aimed at developing WP- 1066 for future therapy ofAML.
Journal ArticleDOI
Treatment with Lenalidomide Has a Positive Immunomodulatory Effect in Patients with Chronic Lymphocytic Leukemia.
Hui Gao,Alessandra Ferrajoli,Evan N. Cohen,Bang-Ning Lee,S Tin,Susan O'Brien,William G. Wierda,Zeev Estrov,Stefan Faderl,Michael J. Keating,James M. Reuben +10 more
TL;DR: Preliminary data suggest that lenalidomide has a favorable immunomodulatory effect on patients with B-CLL and increased the percentages of T-helper cells in both R and NR patients and of T R cells in R patients.
Journal ArticleDOI
Phase I/II Study of Clofarabine Plus Cyclophosphamide in Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL).
Stefan Faderl,Deborah A. Thomas,Varsha Gandhi,Gautam Borthakur,Xuelin Huang,William Plunkett,Jan A. Burger,Jorge E. Cortes,Susan O'Brien,Farhad Ravandi,Jennie Bretz,Monica Kwari,Hagop M. Kantarjian +12 more
TL;DR: Although no MTD has been defined yet and accrual continues in cohort 2, it appears unlikely that the MTD will exceed the dose levels of cohort 2.
Journal ArticleDOI
Hyper-CVAD Plus Nelarabine: A Pilot Study for Patients with Newly Diagnosed T Cell Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LL)
Stefan Faderl,Deborah A. Thomas,Charles Koller,Farhad Ravandi,Jan A. Burger,Susan O'Brien,Samuel Dara,Hagop M. Kantarjian +7 more
TL;DR: Assessment of impact of the nelarabine consolidation on DFS and survival requires higher patient numbers and longer follow up, and hyper-CVAD achieves a high CR rate in T-ALL/LL.